Izotropic Corp. (TSE:IZO)
:IZO
Want to see TSE:IZO full AI Analyst Report?
IZO Stock Chart & Stats
C$0.28
C$0.01(8.33%)
At close: 4:00 PM EST
C$0.28
C$0.01(8.33%)
Day’s Range― - ―
52-Week RangeC$0.19 - C$0.49
Previous CloseN/A
Volume236.24K
Average Volume (3M)43.33K
Market Cap
C$16.90M
Enterprise ValueC$20.36M
Total Cash (Recent Filing)C$364.08K
Total Debt (Recent Filing)C$3.14M
Price to Earnings (P/E)―
Beta-0.19
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding68,984,680
10 Day Avg. Volume24,438
30 Day Avg. Volume43,328
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-2.90
Price to Sales (P/S)0.00
P/FCF Ratio-22.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Reduced Cash BurnThe company materially reduced its cash burn versus prior years, cutting operating and free cash flow losses to about -1.0M TTM. Sustained burn reduction extends runway, lowers near-term refinancing urgency, and gives management more time to complete development and pursue commercialization milestones.
Narrowing LossesA steady reduction in net losses from multi‑million levels to ~2.5M TTM signals improving cost discipline or progress through development stages. This structural improvement enhances financial resilience and increases the probability management can reach breakeven once commercial revenue begins.
Focused Product & Market NicheA dedicated breast CT platform targets a specific clinical need versus general imaging. If regulatory clearance and clinical adoption follow, the differentiated product can create durable competitive positioning, clearer go‑to‑market messaging, and higher unit economics versus commodity imaging modalities.
Bears Say
No Revenue / Negative Gross ProfitAbsence of revenue and negative gross profit mean the business model remains unproven commercially. Structural dependence on future product approvals and adoption increases execution risk; without sales, the firm must rely on external financing to fund operations and commercialization.
Negative Equity & Weak Balance SheetNegative shareholder equity and a small asset base relative to debt indicate accumulated losses and constrained solvency. This structural weakness reduces borrowing capacity, increases refinancing and covenant risk, and raises the likelihood of dilutive capital raises to sustain operations.
Persistent Cash Flow DeficitOngoing negative operating and free cash flow create a recurring financing requirement. Structural dependence on external capital increases dilution or debt risk, constrains investment in commercialization, and can slow clinical and regulatory progress if adequate funding is not secured.
Izotropic News
IZO FAQ
What was Izotropic Corp.’s price range in the past 12 months?
Izotropic Corp. lowest stock price was C$0.19 and its highest was C$0.49 in the past 12 months.
What is Izotropic Corp.’s market cap?
Izotropic Corp.’s market cap is C$16.90M.
When is Izotropic Corp.’s upcoming earnings report date?
Izotropic Corp.’s upcoming earnings report date is Aug 21, 2026 which is in 91 days.
How were Izotropic Corp.’s earnings last quarter?
Izotropic Corp. released its earnings results on Mar 27, 2026. The company reported -C$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.004.
Is Izotropic Corp. overvalued?
According to Wall Street analysts Izotropic Corp.’s price is currently Overvalued.
Does Izotropic Corp. pay dividends?
Izotropic Corp. does not currently pay dividends.
What is Izotropic Corp.’s EPS estimate?
Izotropic Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Izotropic Corp. have?
Izotropic Corp. has 68,984,680 shares outstanding.
What happened to Izotropic Corp.’s price movement after its last earnings report?
Izotropic Corp. reported an EPS of -C$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.174%.
Which hedge fund is a major shareholder of Izotropic Corp.?
Currently, no hedge funds are holding shares in TSE:IZO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Izotropic Corp.
Izotropic Corporation, a MedTech company, commercializes diagnostic products for breast cancer. It develops and commercializes breast CT Imaging system; and 3D CT breast imaging platform for the earlier detection and diagnosis of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.
Technical Analysis
Spectral Medical
―
BioMark Diagnostics
―
Perimeter Medical Imaging AI
―
Sona Nanotech Inc
―
VentriPoint Diagnostics
―
Options Prices
Currently, No data available
---